SCHEMBL3670190

SCHEMBL3670190

O=C(Nc1ccc(Cc2ccncc2)cc1)c1nc2cc(C(F)(F)F)ccc2[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 2/20 0.48
EPAS1 Q99814 2/20 0.48
NAMPT P43490 1/20 0.46
LMNA P02545 4/20 0.45
MAPT P10636 1/20 0.45
MAPK1 P28482 1/20 0.45
JAK2 O60674 1/20 0.45
JAK1 P23458 1/20 0.45
TYK2 P29597 1/20 0.45
KDR P35968 7/20 0.44
FLT1 P17948 6/20 0.44
TSHR P16473 1/20 0.43
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
RAB9A P51151 1/20 0.43
MTOR P42345 1/20 0.43
ABL1 P00519 1/20 0.42
EGFR P00533 1/20 0.42
CSF1R P07333 1/20 0.42
PDGFRB P09619 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3601549 0.85 KDR (0.54) LMNAMAPTMAPK1JAK2JAK1
SCHEMBL3597914 0.83 RAF1 (0.51) HIF1AEPAS1TYK2KDRFLT1
SCHEMBL13408251 0.81 ADRB2 (0.56) LMNAMAPTMAPK1TSHRNPC1
SCHEMBL3587532 0.81 HIF1A (0.46) HIF1AEPAS1NAMPTLMNAMAPT
SCHEMBL3594364 0.81 EGLN1 (0.52) LMNAMAPTTSHRNPC1TP53
SCHEMBL3589751 0.78 KDR (0.53) MAPTMAPK1JAK2TYK2KDR
SCHEMBL3588092 0.77 NPC1 (0.51) LMNAKDRNPC1TP53RAB9A
SCHEMBL32680298 0.77 HRH4 (0.44) NPC1MTORKDM4EALDH1A1NPSR1
SCHEMBL13408250 0.75 KDR (0.65) MAPK1JAK2TYK2KDRFLT1
SCHEMBL30933587 0.73 NTRK1 (0.49) MAPTMTORALDH1A1NTRK1NTRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1643991-B1 BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS MERCK PATENT GMBH (DE) 2014-03-12 EP disclosed
US-7691870-B2 Benzimidazole carboxamides as raf kinase inhibitors MERCK PATENT GMBH (DE) 2010-04-06 US disclosed
US-20070093532-A1 Benzimidazole carboxamides as raf kinase inhibitors MERCK PATENT GMBH (DE) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093532-A1 Benzimidazole carboxamides as raf kinase inhibitors BRAF, RAF1, ARAF HIF1A 955/4885EPAS1 641/4885NAMPT 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.